active
ACTIVE SINCE: 2000

Global Alliance to Eliminate Lymphatic Filariasis (GAELF)

Bringing together a diverse group of public-private health partners to support the Global Programme to Eliminate Lymphatic Filariasis (GPELF) by mobilising political, financial and technical resources to ensure success.
SGDS CONTRIBUTING TO:
SHOW SUB-TARGETS + HIDE SUB-TARGETS -
MEMBER COMPANIES:
Academia or research institute 17
Bilateral development organizations 6
Global NGOs 14
Private Foundation or Development Organization 5
Government 2
Professional and Trade Associations 2
Hospitals Health Facilities 1
Financial Institutions 1
Local NGOs 4
Life Sciences 1
Intergovernmental Organizations and Multilaterals 3
Product Development Partnerships 1
Objectives

The mission of the Global Alliance to Eliminate Lymphatic Filariasis (GAELF) is to bring together a diverse group of public-private health partners to support the Global Programme to Eliminate Lymphatic Filariasis (GPELF) by mobilising political, financial and technical resources to ensure success.

The global programme’s elimination strategy has two components: (1) to stop the spread of infection (interrupting transmission); and (2) to alleviate the suffering of affected populations (controlling morbidity).

GAELF helps coordinate activities of partners and concentrates on political, financial and technical support.

What are the health needs and challenges?

Lymphatic filariasis (LF), or elephantiasis as it is commonly known, is a mosquito-spread infectious disease that affects 120 million people in more than 50 countries worldwide. Another 856 million people are at risk of infection.

Found in the tropical and sub-tropical areas of Africa, Asia, the Pacific, the Middle East and the Americas, LF is one of the world’s leading causes of disability. It is characterised by severe swelling of the legs and arms and skin infections, and many people affected are unable to work and therefore forced into a life of poverty.

Partnership activities and how they address needs and challenges

The World Health Assembly passed resolution 50:29 in 1997 calling on Member States, working with other partners, to take advantage of the simplified and highly effective strategies to eliminate the disease. In support of this goal, the Global Alliance to Eliminate Lymphatic Filariasis (GAELF) was created to foster partnership together with the WHO in order to support the Global Programme in bringing together ministries, implementing organisations, academia and research organisations to coordinate these efforts.

Mass Drug Administration (MDA)

Elimination of LF is possible by stopping the spread of the infection through preventive chemotherapy. The WHO recommended preventive chemotherapy strategy for LF elimination is mass drug administration of albendazole (donated by GSK), MECTIZAN (donated by MSD), and DEC (donated by Eisai).

WHO recommends the following MDA regimens:

  • albendazole (400 mg) alone twice per year for areas co-endemic with loiasis
  • ivermectin (200 mcg/kg) with albendazole (400 mg) in countries co-endemic with onchocerciasis
  • diethylcarbamazine citrate (DEC) (6 mg/kg) and albendazole (400 mg) in countries without onchocerciasis

Following recent evidence that indicates that the combination of all three medicines can safely clear almost all microfilariae from the blood of infected people in a shorter duration, WHO in 2017 recommended the following MDA regimen, called the IDA regimen, in countries without onchocerciasis:

  • ivermectin (200 mcg/kg) together with diethylcarbamazine citrate (DEC) (6 mg/kg) and albendazole (400 mg) in certain settings.
Results and milestones

According to the WHO, from 2000 to 2016, 6.7 billion treatments were delivered to more than 850 million people at least once in 66 countries, considerably reducing transmission in many places. The population requiring MDA has declined by 36% (499 million) where infection prevalence has been reduced below elimination thresholds.

14 countries (Cambodia, The Cook Islands, Egypt, Maldives, Marshall Islands, Niue, Palau, Sri Lanka, Thailand, Togo, Tonga, Vanuatu, Viet Nam and Wallis and Fortuna) are now acknowledged as achieving elimination of LF as a public health problem. Seven additional countries have successfully implemented recommended strategies, stopped large-scale treatment and are under surveillance to demonstrate that elimination has been achieved.

To date, GSK has donated more than 8.5 billion tablets of anti-parasitic medicine, albendazole, to help prevent LF transmission and has committed to donating as much albendazole as needed to the WHO each year until LF is eliminated globally. Eisai has donated approximately 1.9 billion diethylcarbamazine (DEC) tablets to help prevent LF transmission and has committed to continue donating DEC tablets until LF is eliminated globally. MSD has donated so far more than 2.3 billion treatments, including 72 million treatments for IDA countries.

Geographic Reach
  • Global Commitment
Disease Area
  • Infectious and Parasitic Disease
See Disease Areas
Target Population
  • Children
  • Youth
  • Women
  • Men
  • Elderly
  • People with low incomes
  • Marginalized/indigenous people
  • Rural populations
Partner organizations
Academia or research institute

Liverpool School of Tropical Medicine

London School of Hygiene & Tropical Medicine (LSHTM)

Nagasaki University

London Centre for Neglected Tropical Disease Research

Centro de Investigacao em Saude de Angola (CISA)

Eastern & Southern Africa Centre of International Parasite Control (ESACIPAC)

Escola Superior de Tecnologia da Saúde de Lisboa Portugal

Ethiopian Public Health Institute (EPHI)

Global Atlas of Helminth Infections (GAHI)

Government TD Medical College Kerala India

Kwame Nkrumah University of Science & Technology

Case Western Reserve University

African Research Network for Neglected Tropical Diseases (ARNTD)

Indian Council of Medical Research

James Cook University

KEMRI-Wellcome Trust Research Program

Kenya Medical Research Institute

Bilateral development organizations

US Agency for International Development (USAID)

Kuwait Fund

Saudi Fund for Development

Australian Agency for International Development (AUSAID)

Department for International Development (DFID)

Japan International Cooperation Agency (JICA)

Global NGOs

International Foundation for Dermatology

NTD NGDO Network (NNN)

Carter Center

Catholic Medical Mission Board

Christian Blind Mission International (CBMI)

Girl Effect

Handicap International

International Volunteers in Urology

LEPRA

Sightsavers International

Leprosy Mission International

Drugs for Neglected Diseases initiative (DNDi)

Effect Hope (The Leprosy Mission Canada)

IMA World Health

Private Foundation or Development Organization

Health & Development International (HDI)

Footwork

Bill and Melinda Gates Foundation

Childrens Investment Fund Foundation (CIFF)

Izumi Foundation

Government

Ministry of Health, Labour and Welfare Japan

Centers for Disease Control and Prevention (CDC)

Professional and Trade Associations

International Skin Care Nursing Group

European Foundations Initiative for African Research into NTDs (ARNTD)

Hospitals Health Facilities

Amaury Coutihno, Brazil

Financial Institutions

Arab Fund for Economic and Social Development

Local NGOs

Mission to Save the Helpless, Nigeria

Charitable Society for Social Welfare (CSSw) Yemen

Children Without Worms

Helen Keller International

Life Sciences

Inverness Medical Professional Diagnostics, USA

Intergovernmental Organizations and Multilaterals

UNICEF

World Bank

World Health Organization (WHO)

Product Development Partnerships

Mectizan Donation Program